CASE REPORT article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1608733
This article is part of the Research TopicEvidence-Based Research and Clinical Application of Adverse Reactions and Management Strategies for Cancer Treatment DrugsView all 5 articles
Case report: Osimertinib-induced acute interstitial lung disease
Provisionally accepted
- 1Department of Thoracic Surgery.Ziyang City Central Hospital, Ziyang, China
- 2Department of Infectious Diseases, Ziyang City Central Hospital, Ziyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Osimertinib is a third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively targets EGFR-TKI-sensitive mutations, thereby inhibiting tumor cell proliferation, migration, and invasion. Herein, we present a case of osimertinib-induced interstitial lung disease (ILD) in an 80-year-old woman with EGFR-mutated lung adenocarcinoma. The patient was treated with osimertinib as first-line therapy for metastatic non-small cell lung cancer (NSCLC).On day 45 of treatment, she experienced acute onset of severe dyspnea, which rapidly progressed to diffuse bilateral pulmonary consolidation and profound hypoxemia. Despite discontinuation of osimertinib and administration of aggressive supportive care, her clinical condition continued to deteriorate, ultimately resulting in a fatal outcome. This case underscores the importance of monitoring respiratory symptoms in patients receiving EGFR-TKIs, promptly diagnosing ILD, and implementing early intervention to mitigate adverse outcomes.
Keywords: Adverse Drug Reaction, Osimertinib, Interstitial Lung Disease, lung cancer, EGFR-TKI
Received: 09 Apr 2025; Accepted: 19 May 2025.
Copyright: © 2025 Lin, Wu, Yu, Jiang, Yang and Guibao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yanchun Yang, Department of Thoracic Surgery.Ziyang City Central Hospital, Ziyang, China
Xiao Guibao, Department of Infectious Diseases, Ziyang City Central Hospital, Ziyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.